MARKET

IMUC

IMUC

Immunocellular
OTCPK

Real-time Quotes | Nasdaq Last Sale

0.300
-0.000
-0.07%
Opening 12:06 05/23 EDT
OPEN
0.300
PREV CLOSE
0.300
HIGH
0.300
LOW
0.300
VOLUME
250
TURNOVER
75
52 WEEK HIGH
0.750
52 WEEK LOW
0.140
MARKET CAP
1.26M
P/E (TTM)
-0.0631
1D
5D
1M
3M
1Y
5Y
ImmunoCellular Therapeutics Announces Application for Continued Public Quoting on the Over-the-Counter (OTC) Market
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (OTC: IMUC), today announced that the Company has taken steps to comply with amended Rule 15c2-11 under the Securities and Exchange Act which will be applicable in September 2021. The amended Rule requir...
PR Newswire · 06/28/2021 10:00
ImmunoCellular Therapeutics Announces Results of Special Meeting of Stockholders Held June 26, 2020
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (OTC: IMUC), today announced that, based on the vote count following the Special Meeting of Stockholders held June 26, 2020, stockholders voted in favor of the proposal to approve an amendment to the Company
PR Newswire · 07/02/2020 20:05
ImmunoCellular Therapeutics Announces Settlement of Derivative Action Lawsuit
PR Newswire · 10/16/2019 20:05
No Data
Learn about the latest financial forecast of IMUC. Analyze the recent business situations of Immunocellular through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
EPS
Actual
Estimate
-9.13-6.85-4.56-2.28
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Institutional Holdings
Institutions: 1
Institutional Holdings: 95
% Owned: 0.00%
Shares Outstanding: 4.19M
TypeInstitutionsShares
Increased
0
0
New
0
0
Decreased
0
0
Sold Out
3
276.60K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.83%
Pharmaceuticals & Medical Research
+0.95%
Key Executives
Lead Director
Rahul Singhvi
Director
John Yu
Independent Director
Gregg Lapointe
Independent Director
Mark Schlossberg
Independent Director
Gary Titus
No Data
No Data
About IMUC
ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is developing immune-based therapies for the treatment of cancers. The Company's cancer immunotherapies target cancer stem cells (CSCs), which are the drivers of tumor growth and disease recurrence. Its product candidate is ICT-107, which is in phase III testing. In addition, the Company also has a portfolio of other potential therapeutic immunotherapies using a range of approaches to treat cancer. Its other product candidates are ICT-140 and ICT-121. ICT-107 is a dendritic cell (DC) vaccine for the treatment of newly diagnosed glioblastoma multiforme (GBM), a type of brain cancer. ICT-140 is a DC vaccine that targets over seven tumor-associated antigens expressed on ovarian cancer cells. It is developing ICT-121, a dendritic cell (DC)-based vaccine targeting CD133+ CSCs for the treatment of recurrent GBM and other solid tumor cancers, including ovarian, pancreatic and breast cancers.

Webull offers kinds of ImmunoCellular Therapeutics Ltd stock information, including OTCPK:IMUC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMUC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IMUC stock methods without spending real money on the virtual paper trading platform.